Amgen’s IMDELLTRA combo cuts death hazard 58%: AMGN stock forecast

Amgen said on October 24 that adding IMDELLTRA to IMFINZI reduced the hazard of death by 58% versus IMFINZI alone in a Phase 3 lung-cancer trial. Its DeLLphi-305 announcement, issued at 10:30 a.m. EDT, strengthens the case for using the drug earlier in treatment.

For investors, the Amgen stock forecast turns on how that clinical advance changes earnings expectations. TECHi’s calculation puts Friday’s closing price at 19.2 times the midpoint of Amgen’s annual adjusted earnings guidance. At that same multiple, a 10% share-price gain would require roughly $1.25 billion more annual adjusted net income, assuming the latest reported diluted share count stays unchanged. That is a valuation sensitivity, not a prediction of IMDELLTRA’s profit.

The stock starts at 19.2 times management’s earnings midpoint

Amgen shares closed at $439.26 on Friday, October 23, at 4 p.m. EDT. That regular-session observation is in U.S. dollars and predates Saturday’s disclosure. U.S. stock markets are closed for the weekend; Friday’s price cannot establish how investors reacted to these results.

Amgen’s second-quarter financial report gave 2026 non-GAAP earnings guidance of $22.30 to $23.50 per share. The midpoint is $22.90. Dividing $439.26 by $22.90 produces 19.18, rounded here to 19.2 times. This deliberately uses management’s dated annual guidance rather than mixing a historical price with an unspecified forward analyst estimate.

The choice of earnings measure matters. Amgen also guided to GAAP EPS of $15.80 to $17.08. The $16.44 midpoint implies a substantially higher 26.72 times earnings at the same price. Adjusted earnings remove specified accounting items; they do not turn the stock into an objectively cheap investment. Investors using the adjusted framework should retain the company’s reconciliation and assess the costs it excludes.

What a 10% gain would actually require

A hypothetical 10% increase from Friday’s close gives $483.19, rounded to cents. There are different ways to reach that price: higher annual earnings, a higher multiple, or a combination of both. The table separates those paths while holding everything else constant. It is arithmetic against the current guidance baseline, not a set of analyst targets or an assigned probability distribution.

The earnings-only route requires $25.19 per share, an increase of $2.29 from the guidance midpoint. Using the 544 million diluted shares reported for the second quarter, that corresponds to approximately $1.246 billion in additional annual adjusted net income. A different future share count would change the required total profit, although the per-share arithmetic would stay the same.

That calculation does not mean IMDELLTRA must produce the entire increase. Other drugs, costs, taxes and repurchases also affect Amgen’s earnings. Nor does it mean a trial result must generate that profit immediately before the market can respond. Shares can revalue expected future cash flows well before a new indication generates commercial revenue.

The useful question is how much of the new opportunity was already embedded in investors’ expectations. A strong result can improve confidence in an existing forecast without increasing that forecast by the full potential sales opportunity. Adding an entire prospective business on top of a model that already assigns it substantial value would double count the same success.

The opposite is possible too. If the result supports a materially larger eligible population or more durable use than investors had assumed, future estimates could rise substantially. Identifying which case applies requires updated commercial assumptions, not a mechanical translation of the clinical percentage into a share-price percentage.

Why earlier use changes the commercial question

The study enrolled 563 patients whose extensive-stage small-cell lung cancer had not progressed after initial durvalumab and chemotherapy. Amgen reported median survival of 21.1 months with the combination versus 12.7 months with durvalumab alone, an 8.4-month difference. About 80% versus 53% were alive at one year. These are interim trial outcomes, not guaranteed benefits for individual patients.

The 58% figure is a relative reduction in the hazard of death over follow-up. It does not mean survival increased by 58 percentage points. Using the rounded one-year figures gives an approximately 27-percentage-point difference at that particular time. Keeping those measures separate avoids overstating what the result says.

Commercially, the important change is the proposed treatment setting. The FDA’s existing approval covers adults whose disease progressed on or after platinum-based chemotherapy. The newly reported maintenance study concerns patients who had not progressed after initial treatment. A successful expansion could therefore reach patients earlier, but a trial announcement is not authorization for that additional use.

A forecast also needs to distinguish additional patients from treatment shifted earlier. If some patients who would otherwise receive IMDELLTRA later instead start during maintenance, counting both full revenue streams would overstate the incremental opportunity. Longer treatment duration could increase sales, while discontinuations, competing regimens and access restrictions could reduce them. The direction and size require evidence that this clinical release alone cannot supply.

Approval and delivery are separate investment milestones

The first checkpoint is regulatory: the filing scope, acceptance and eventual decision will define the commercial opportunity more precisely. No approval date for this new setting is assumed in this forecast. A strong survival result improves the evidence supporting an application; it does not establish its timetable, final label or reimbursement conditions.

Safety and administration also affect the route from an approved therapy to recurring sales. The FDA’s approval notice identifies boxed warnings for cytokine-release syndrome and neurologic toxicity, including ICANS. Those requirements matter to care settings and monitoring resources as well as patients. They should remain in the investment assessment alongside efficacy.

In DeLLphi-305, Amgen reported severe treatment-related adverse events in 20.9% of combination recipients versus 10.8% with durvalumab alone. Those trial-specific figures should not be mixed with pooled safety rates from other studies. The company’s favorable overall characterization does not erase the practical demands of delivering another therapy.

A credible commercial forecast would specify eligible patients, uptake, net realized revenue per patient, duration and incremental expenses. It would then subtract any displaced later-line sales and account for taxes. Without those inputs, attaching a precise revenue number to the clinical result would create an appearance of certainty that the evidence does not support.

The bullish case is stronger; the price target is still conditional

TECHi’s near-term assessment is constructive on the clinical catalyst, with the size of a sustainable stock revaluation still unresolved. Through the next earnings update, the most informative development would be a clearer commercial or regulatory path. Over the following six to twelve months, evidence that the opportunity adds to expected earnings would matter more than repeatedly citing the initial efficacy headline.

The strongest bullish argument is that uncertainty itself has value. A convincing trial can increase the probability assigned to a future revenue stream and support a higher multiple before current-year EPS changes. The table’s unchanged-EPS route illustrates that mechanism: the same $22.90 multiplied by about 21.10 reaches the illustrative 10%-higher price. It does not prove investors will choose that multiple.

The restrained case is that clinical enthusiasm improves sentiment while company-wide earnings expectations move less. Amgen is a diversified business, so a promising oncology development has to be assessed alongside the rest of its portfolio and spending. The new result does not neutralize unrelated commercial pressures or financing costs. A forecast based on one asset should not silently treat every other earnings input as guaranteed.

The downside case is a delay or a narrower commercial opportunity than investors anticipate, combined with a lower willingness to pay for earnings. For scale, a 5% reduction in the $22.90 earnings baseline, with the same starting multiple, implies about $417.30. That is a sensitivity rather than a downside target; simultaneous multiple compression would produce a larger decline. The clinical result can remain positive while shareholders experience a negative return.

These cases make the next research task concrete. Compare any change in earnings estimates with the assumptions behind it, then ask how much additional optimism the share price requires. Readers can use TECHi’s AMGN forecast page to compare dated market estimates, while keeping this article’s fixed Friday price and management-guidance baseline separate from subsequently refreshed figures.

What to watch

Monday, October 26, is the next scheduled U.S. regular trading session. Its opening reaction will provide the first regular-session price comparison after Saturday’s announcement, but a move alone will not prove the drug’s future revenue. Amgen’s November 3 earnings conference call, scheduled for 1:30 p.m. PST, is the next dated company checkpoint. Watch for filing plans, commercial assumptions and changes to earnings guidance that could substantiate a revised valuation.